FierceBiotech5h
Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1
The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...
labiotech3h
Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses
Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
Yahoo Finance12h
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
In the last year, for instance, GSK, Pfizer and more recently Moderna have all brought ... The company will also use its ...
ENDPOINTS NEWS5h
UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...